AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, Aug. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced a public offering of 5,068,138 shares of common stock at a price of $31.00 per share under shelf registration statements previously filed and declared effective by the Securities and Exchange Commission (SEC). Net proceeds to Amylin are expected to be approximately $152 million. A prospectus supplement relating to the offering will be filed with the SEC by Amylin, and will be available along with the base prospectuses filed with the SEC in connection with the shelf registrations, on the SEC's website at http://www.sec.gov/. Goldman, Sachs & Co. is the sole underwriter for this offering. Printed copies of the prospectus supplement and base prospectuses relating to the offering may also be obtained, when available, from Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Phone: 212-902-1000). This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The common stock is being offered in connection with a distribution by the issuer and represents a new financing. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright